Diabetes Therapy最新文献

{"title":"Pen Needle Reuse in People with Diabetes Who Inject Insulin: A Narrative Review.","authors":"Diana Isaacs, Davida Kruger, Susan Cornell, Sanjay Kalra, Sandro Gentile","doi":"10.1007/s13300-026-01900-5","DOIUrl":"10.1007/s13300-026-01900-5","url":null,"abstract":"<p><strong>Introduction: </strong>Global rates of insulin pen needle (PN) reuse in people with diabetes (PWD) vary across regions. However, it is estimated that more than 50% of PWD will reuse their PNs at some point over the course of their disease management. This highlights the need for better education to avoid this practice, which can lead to complications such as lipohypertrophy, pain, and poor glycemic management. This review aims to educate healthcare professionals (HCPs) on the issues surrounding PN reuse by PWD; discuss the scientific and clinical rationale for and against PN reuse; provide guidance on best practice for PN use by PWD who use insulin when reuse continues or is unavoidable; and provide actionable insights for clinical education and person-centered support interventions.</p><p><strong>Methods: </strong>To compile the data on PN reuse, a PubMed search was conducted in November 2025, with \"diabetes\", \"insulin\", and \"needle reuse\" as the search terms. Over 100 articles were found and assessed for inclusion based on scientific vigor, leaving approximately 40 articles for inclusion.</p><p><strong>Results: </strong>The main reasons for PN reuse were stated to be convenience and cost in many regions around the world.</p><p><strong>Conclusions: </strong>The findings of this review suggest that reducing PN reuse rates requires continued, ongoing education about injection technique and potential complications of PN reuse. Ideally, this education should be provided by HCPs and diabetes educators, as they are the most trusted source of information for PWD. It is vital to determine the reasons for reuse without judgment and discuss suitable solutions to mitigate the problem.</p>","PeriodicalId":11192,"journal":{"name":"Diabetes Therapy","volume":" ","pages":"1269-1287"},"PeriodicalIF":4.2,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13546391/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148469466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insulin Injection Behaviors and Association with Glycemic Outcomes in Patients with Diabetes: A Real-World Survey in Spain.","authors":"Alba Galdón Sanz-Pastor, Alicia Justel Enríquez, Ana Sánchez Bao, Rosa P Quílez Toboso, Beatriz González Aguilera, Mercedes Noval Font, Jessica Ares Blanco, Inés Modrego Pardo, Beatriz Voltas Arribas, Francisco Javier Ampudia-Blasco","doi":"10.1007/s13300-026-01897-x","DOIUrl":"10.1007/s13300-026-01897-x","url":null,"abstract":"<p><strong>Introduction: </strong>Optimal glycemic control is essential to prevent complications in diabetes, and insulin administration practices play a key role. This study assessed insulin injection behaviors and related glycemic outcomes among individuals using multiple daily injections in Spain.</p><p><strong>Methods: </strong>A cross-sectional online survey was conducted via an independent patient platform (Canal Diabetes). Adults (18-65 years) with type 1, type 2, or other forms of diabetes (e.g., maturity-onset diabetes of the young (MODY) or secondary diabetes) requiring daily insulin injections were included. Demographic, clinical, and behavioral data were analyzed using SPSS Statistics, version 23 (IBM Corp., Armonk, NY, USA).</p><p><strong>Results: </strong>Among 288 participants (mean age: 43.7 ± 14.7 years; 28.8% male, 71.2% female), 74.7% had type 1 diabetes. Most were white (95.8%) with a mean diabetes duration of 17.8 ± 14.5 years. While 83.3% injected prandial insulin before meals, only 71.2% did so at least 15 min before eating. Errors were frequent: 38.5% reported underdosing and 26.7% overdosing more than five times in the past month. Participants injecting before meals had significantly better outcomes than those injecting at other times, including higher rates of glycated hemoglobin (HbA1c) ≤ 7.5% (83.3% versus 62.5%, p = 0.001), greater time in range (TIR) (74.4% versus 66.3%, p = 0.032), and lower mean glucose (144 versus 159 mg/dL, p = 0.019). Smart pen users (41.2%) reported fewer mild-to-moderate hypoglycemic events (p = 0.021), though no differences were observed in HbA1c or TIR.</p><p><strong>Conclusion: </strong>Insulin injection practices in Spain reveal significant variability and opportunities for improvement. Promoting timely premeal insulin administration and leveraging technologies such as smart pens may improve glycemic outcomes.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov identifier, NCT06421467.</p>","PeriodicalId":11192,"journal":{"name":"Diabetes Therapy","volume":" ","pages":"1369-1384"},"PeriodicalIF":4.2,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13546270/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148600179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glycemic Patterns Assessed by Continuous Glucose Monitoring in People with Type 2 Diabetes Treated with Insulin Glargine 100 U/mL in Primary Care: The GPDetect Study.","authors":"Virginia Bellido, Ana Cebrián, Cristóbal Morales, Alberto S de Las Hazas, Alfonso Soto-Gonzalez, Carla Morer-Liñan, José M Borrachero, Gabriel Cuatrecases, Elena L García, Judith López-Fernández, Silvia Lozano-García, Álvaro M Bayón, Cristina M Niño-Azcarate, Oscar Laclaustra, Paulina Fuentealba","doi":"10.1007/s13300-026-01903-2","DOIUrl":"10.1007/s13300-026-01903-2","url":null,"abstract":"<p><strong>Introduction: </strong>Hypoglycemia is a common complication in people with type 2 diabetes mellitus (T2DM) treated with basal insulin, yet its true prevalence in real-world primary care remains underexplored. This study used blinded continuous glucose monitoring (CGM) to assess glycemic patterns in patients with T2DM on basal insulin-supported oral therapy (BOT) with insulin glargine 100 U/mL (Gla-100) in Spain.</p><p><strong>Methods: </strong>GPDetect was a prospective, multicenter, observational study in adults with T2DM treated with Gla-100 for ≥ 6 months in primary care. Participants underwent 14 days of blinded CGM (FreeStyle Libre^® Pro iQ^®). The primary objective of the present study was to estimate the proportion of patients with T2DM treated with Gla-100 whose TBR (glucose < 70 mg/dL) exceeded the internationally recommended threshold of 4%. Secondary endpoints included time in range (TIR), time above range (TAR), episodes of clinically significant hypoglycemia (< 54 mg/dL), cognitive function (MMSE), and fear of hypoglycemia (EsHFS).</p><p><strong>Results: </strong>Among 136 patients (mean age 69 years), 16.9% had TBR > 4%, with a higher prevalence at night (23.5%) than during the day (12.5%). Clinically significant hypoglycemia (< 54 mg/dL > 1%) occurred in 8.8% of patients. Hyperglycemia was common: 46.3% spent > 25% of the day between 181-250 mg/dL, and 28.7% spent time > 250 mg/dL. Only 55.9% achieved TIR ≥ 70%. Patients receiving SGLT2i had lower mean glucose and EsHFS scores. Cognitive impairment (MMSE < 23) was associated with longer hypoglycemia duration.</p><p><strong>Conclusions: </strong>Blinded CGM revealed a relevant burden of unrecognized hypoglycemia-particularly nocturnal-as well as daytime hyperglycemia in patients with T2DM treated with Gla-100 in primary care. These results support the clinical value of CGM in informing treatment decisions and improving individualized diabetes management.</p>","PeriodicalId":11192,"journal":{"name":"Diabetes Therapy","volume":" ","pages":"1385-1405"},"PeriodicalIF":4.2,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13546280/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148677473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implementing SGLT2 Inhibitor Therapy in Line with the New NICE Guidelines for Type 2 Diabetes Management.","authors":"Philip Newland-Jones, Partha Kar, Beth Kelly, Rahul Mohan, Sarah Davies, Jane Diggle, Marc Evans, Kevin Fernando, Debbie Hicks, Naresh Kanumilli, Nicola Milne, Dipesh Patel, Samuel Seidu, Adie Viljoen, David C Wheeler, John P H Wilding","doi":"10.1007/s13300-026-01889-x","DOIUrl":"10.1007/s13300-026-01889-x","url":null,"abstract":"<p><p>The latest type 2 diabetes mellitus (T2DM) management guidelines from the UK National Institute for Health and Care Excellence (NICE; NG28) have raised the profile of sodium-glucose cotransporter-2 inhibitors (SGLT2is) so that they are now the preferred first-line therapy in combination with modified-release metformin (or as monotherapy where metformin is contraindicated/not tolerated) for most individuals. Previous NICE recommendations limited use to those with high cardiovascular disease (CVD) risk or existing CVD and/or kidney disease for first-line treatment or people with a need for additional glycaemic optimisation at later stages in the pathway. This change brings the guidelines in line with other national and international recommendations regarding SGLT2i use for the achievement and maintenance of glycaemic targets and lowering of progressive risk for cardiovascular, renal and metabolic (CVRM) complications. Yet, despite a plethora of evidence supporting the role that SGLT2is can play in sustaining long-term health outcomes in people with T2DM, prescribing data from real-world clinical practice show that these therapies are under-prescribed, particularly among those populations most likely to benefit from their use (including individuals with CVD or high CVRM risk). This latest narrative review from the Improving Diabetes Steering Committee examines the place of SGLT2is within the latest NG28 guidelines and likely reasons for suboptimal SGLT2i use, providing pragmatic advice on appropriate approaches to initiation and management in daily practice and setting perceived risks into context against the potential benefits. Practical tools for healthcare professionals and people with T2DM are included, and the Committee's previously published SGLT2i Prescribing Decision Tool for T2DM Management has been updated and aligned with the most recent guidelines with the aim of providing a helpful and high-quality quick reference resource.</p>","PeriodicalId":11192,"journal":{"name":"Diabetes Therapy","volume":" ","pages":"1095-1117"},"PeriodicalIF":4.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13457809/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148430046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond Coverage Expansion: Exploring Persistent Barriers to CGM Utilization in the Clinical Environment.","authors":"Consuela Coni Dennis, Victoria Bouhairie","doi":"10.1007/s13300-026-01894-0","DOIUrl":"10.1007/s13300-026-01894-0","url":null,"abstract":"<p><p>Continuous glucose monitoring (CGM) improves glycemic control and reduces acute events, yet adoption remains low despite expanded coverage. Real-world evidence shows that most eligible patients do not use CGMs, highlighting a gap between access and utilization. This commentary examines key barriers, including provider knowledge gaps, administrative complexity, workflow constraints, and persistent socioeconomic inequities. We argue that coverage expansion alone is insufficient to drive uptake. Coordinated strategies that support prescriber education, streamline processes, and integrate CGM into routine care are needed. Addressing these systemic and behavioral barriers is essential to realizing the full clinical and economic benefits of CGM at scale.</p>","PeriodicalId":11192,"journal":{"name":"Diabetes Therapy","volume":" ","pages":"1085-1093"},"PeriodicalIF":4.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13457998/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148560860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel Clinical and Pre-clinical Obesity Estimates in Older Indian Adults: Insights from a Nationally Representative Dataset.","authors":"Madhur Verma, Pritam Halder, Aditi Aditi, Nitin Kapoor, Vandana Esht, Waseem Mumtaz Ahamed, Rakesh Kakkar, Sanjay Kalra","doi":"10.1007/s13300-026-01887-z","DOIUrl":"10.1007/s13300-026-01887-z","url":null,"abstract":"<p><strong>Introduction: </strong>Obesity is a multifactorial condition that is not well captured by conventional anthropometry. Emerging frameworks, including the Lancet Commission approach, objectively stratify obesity and provide a more clinically informative characterization of the burden. The present study compares obesity estimates based on conventional BMI criteria with those derived using the revised framework and examines the distribution and determinants of pre-clinical and clinical obesity (CO) among older Indian adults.</p><p><strong>Methods: </strong>We used data from the first wave of the Longitudinal Aging Study in India (2017-2018), including 59,854 adults aged ≥ 45 years. A high body mass index (BMI; > 25 kg/m²) was used to estimate the conventional obesity burden. Pre-clinical obesity and CO were defined using framework guidance and based on variables available in datasets. Weighted prevalence and multivariable logistic regression estimates were calculated using Stata version 16.0.</p><p><strong>Results: </strong>Weighted prevalence of high BMI was 27.1% (95% confidence interval: CI 21.5-33.5), while the prevalence of pre-clinical obesity and CO was 27.0% (21.4-33.4) and 15.1% (10.9-20.6), respectively. CO showed marked geographic variation, with the lowest prevalence in Central India (7.77%) and the highest in South India (24.33%); Meghalaya had the lowest state-level prevalence (4.52%) and Chandigarh the highest (37.88%). Women, urban residents, and participants with higher education and wealth had higher odds of both obesity states. Participants with pre-clinical obesity more often reported excellent self-rated health, whereas poor self-rated health was more common among those with CO.</p><p><strong>Conclusion: </strong>The revised framework meaningfully differentiates high BMI burden into pre-clinical and CO and identified sociodemographic and spatial disparities. Such classification may help distinguish excess adiposity from obesity with morbidity and functional limitation, although interpretation should remain cautious given the proxy operationalization possible within survey data.</p>","PeriodicalId":11192,"journal":{"name":"Diabetes Therapy","volume":" ","pages":"1135-1157"},"PeriodicalIF":4.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13457515/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148270651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Basal Insulin Adherence in Patients with Type 2 Diabetes Mellitus in Routine Clinical Practice in Spain: Clinical and Economic Impact.","authors":"Dídac Mauricio, Virginia Pascual, Maria Soler, Francisco J Pérez-Sádaba","doi":"10.1007/s13300-026-01892-2","DOIUrl":"10.1007/s13300-026-01892-2","url":null,"abstract":"<p><strong>Introduction: </strong>Type 2 diabetes mellitus (T2DM) imposes a clinical and economic burden, largely due to its long-term micro- and macrovascular complications. To prevent these complications, treatment adherence is essential. The aim of this study was to analyse basal insulin adherence and its clinical and economic repercussions in patients with T2DM in Spain.</p><p><strong>Methods: </strong>Retrospective, descriptive observational study using the Spanish Health Improvement Network (THIN®) database. Adult patients with T2DM, a registry entry of first basal insulin prescription from January 2014, and prescription/dispensation records between January 2014 and January 2024 were included. Adherence was estimated as proportion of days covered ≥ 80% in patients with ≥ 1 (full-population) and ≥ 3 years of follow-up (≥ 3 years subpopulation). Sociodemographic, clinical characteristics, micro- and macrovascular complications incidence, healthcare resource use (HCRU) (outpatient general practitioner/nursing/specialists visits and laboratory tests), and sick leave were analysed in adherent and non-adherent patients of the ≥ 3 years subpopulation. Direct (complications + HCRU) and indirect costs were calculated.</p><p><strong>Results: </strong>A total of 9441 patients in the full-population and 4693 in the ≥ 3 years subpopulation were included. Less than 70% were adherent (66.90% and 69.51%, respectively). Although adherent patients tended to be older and more were retired, sociodemographic and clinical characteristics were consistent in adherent and non-adherent patients. In both groups, 17-20% had micro- and 30-40% had macrovascular complications, but non-adherent patients showed increases of 5.54% and 15.90% in annual complications. Mean annual costs for micro- and/or macrovascular complications were €1091.68 for adherent and €1306.45 for non-adherent patients. Mean annual direct and indirect costs were €1528.45 and €784.97 in adherent and €1651.39 and €952.89 in non-adherent patients.</p><p><strong>Conclusion: </strong>This study shows less than 70% adherence to basal insulin under routine clinical practice in Spain and reveals unmet needs in current T2DM therapies. Non-adherence could result in more complications, which would lead to higher costs for the healthcare system.</p>","PeriodicalId":11192,"journal":{"name":"Diabetes Therapy","volume":" ","pages":"1159-1170"},"PeriodicalIF":4.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13457819/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148301185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiometabolic Effects of Semaglutide in Individuals with Type 2 Diabetes in the United Arab Emirates: Real-World 12-Month Outcomes and Predictors of Response.","authors":"Muhammad Hamid Siddique Mian, Kholood Abdulla Hasan Abdulla Janahi, Afnan Tayeb, Fathima Musfira Mohamad Musaffar, Nur Al Sheykh Khalil, Sarah Hisham Al Toubah, Abdul Moen Abdul Karim, Ahlam Almarzooqi, Fardeen Mohammad Sayfoo, Ahmed Hamadeh, Mohannad Abdulla Hasan Abdulla Janahi, Sobia Siddiq","doi":"10.1007/s13300-026-01888-y","DOIUrl":"10.1007/s13300-026-01888-y","url":null,"abstract":"<p><strong>Introduction: </strong>There is little real-world evidence on semaglutide effectiveness in the United Arab Emirates (UAE), despite the high local burden of type 2 diabetes (T2DM) and obesity. The aim of this study was to evaluate real-world cardiometabolic outcomes and predictors of response following initiation of semaglutide in a tertiary endocrine clinic.</p><p><strong>Methods: </strong>This was a retrospective, observational cohort study of adults with T2DM initiating once-weekly subcutaneous semaglutide (June 2022 to January 2025). Primary outcomes were changes in glycated hemoglobin (HbA1c), body weight, and systolic blood pressure (SBP) at 6 and 12 months. Responder and composite endpoints were assessed at 12 months. Predictors of glycemic (HbA1c reduction ≥ 1%) and composite response (HbA1c reduction ≥ 1% and ≥ 5% weight loss) were analyzed by multivariable logistic regression.</p><p><strong>Results: </strong>In total, 278 patients were included. Adjusted HbA1c decreased by -0.89% (95% confidence interval (CI) -1.07 to -0.70) at 6 months and -0.71% (95% CI -0.91 to -0.50) at 12 months (both p < 0.001). Weight decreased by -3.09 kg (-4.19 to -2.00) and -4.77 kg (-6.00 to -3.53) at 6 and 12 months, respectively (p < 0.001). SBP decreased by -3.56 mmHg (-6.17 to -0.96; p = 0.007) at 6 months. Overall, 39% achieved an HbA1c reduction ≥ 1%, 43% achieved ≥ 5% weight loss, and 23% achieved the composite endpoint at 12 months. Higher baseline HbA1c predicted HbA1c response (odds ratio [OR] 1.85; 95% CI 1.26 to 2.88).</p><p><strong>Conclusion: </strong>Semaglutide improved glycemia and weight and resulted in modest reductions in SBP in real-world practice. These findings support semaglutide as an effective component of cardiometabolic risk reduction strategies in adults with T2DM in the region, especially in those with at-risk glycemic profiles.</p>","PeriodicalId":11192,"journal":{"name":"Diabetes Therapy","volume":" ","pages":"1119-1133"},"PeriodicalIF":4.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13457989/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148249715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Performance of the MiniMed 780G Advanced Hybrid Closed Loop Automated Insulin Delivery System in Greece.","authors":"Vaia Lambadiari, Nikolaos Tentolouris, Andriani Vazeou, Athanasios Christoforidis, Christina Kanaka-Gantenbein, Konstantinos Makrilakis, Triantafyllos Didangelos, Maria-Joanna Juachon, Vittorino Smaniotto, Tim van den Heuvel, Goran Petrovski","doi":"10.1007/s13300-026-01883-3","DOIUrl":"10.1007/s13300-026-01883-3","url":null,"abstract":"<p><strong>Introduction: </strong>Real-world studies have demonstrated the effectiveness of automated insulin delivery systems in managing people with type 1 diabetes (T1D) worldwide. However, data on the effectiveness of such systems in the management of people with T1D in Greece have previously been lacking. This retrospective analysis sought to address this by providing real-world insights into the impact of the MiniMed 780G system on the glycemic control of people with T1D in Greece.</p><p><strong>Methods: </strong>Data from MiniMed 780G systems, uploaded to the CareLink Personal Software program between January 2024 and January 2025 by 2284 users with T1D in Greece, were collected and analyzed. Outcomes considered included glycemic control measures such as time spent in target ranges, glucose management indicator (GMI), and international glycemic control targets. Data were analyzed across different age groups (≤ 15 years, 16-55 years, ≥ 56 years), with additional analyses of cohorts using recommended optimal settings (ROS), users with data from before and after the initiation of the advanced hybrid closed-loop system, and users with 12 months of data.</p><p><strong>Results: </strong>Across the overall cohort, the mean (standard deviation [SD]) time in range (TIR) was 75.4% (9.5%), and 59.3% of users achieved a combined target of a GMI < 7%, TIR > 70%, time below 70 mg/dl < 4%, and time below 54 mg/dl < 1%. These findings were consistent across age groups and stable over a 12-month period, but were found to be better among users with ROS. Comparing data obtained before and after the initiation of the system, mean (SD) TIR was found to increase from 65.1% (13.9%) to 74.9% (9.6%), while the proportion of users achieving a TIR of > 70% increased from 36.1 to 72.8%.</p><p><strong>Conclusion: </strong>These data demonstrate that most users of the MiniMed 780G system achieve the recommended glycemic control targets.</p>","PeriodicalId":11192,"journal":{"name":"Diabetes Therapy","volume":" ","pages":"1187-1200"},"PeriodicalIF":4.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13457521/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148351006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Time-Averaged Serum Uric Acid and Renal Outcomes in Patients with Type 2 Diabetes Mellitus with Chronic Kidney Disease: A Multicenter Retrospective Cohort Study.","authors":"Shaogui Zhang, Xuan Zhao, Jianteng Xie, Yifan Zhang, Yanhui Wang, Xiaojie Chen, Qiuling Li, Danfeng Liu, Runli Jia, Weiting He, Yaxi Zhu, Hanchen Hou, Sheng Li, Fanna Liu, Yiming Zhang, Rongshao Tan, Hongquan Peng, Jie Li, Wenjian Wang","doi":"10.1007/s13300-026-01895-z","DOIUrl":"10.1007/s13300-026-01895-z","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of this work is to explore the association of time-averaged serum uric acid (TA-SUA) with renal outcomes of type 2 diabetes mellitus (T2DM) with chronic kidney disease (CKD).</p><p><strong>Methods: </strong>A cohort of T2DM with CKD from eight centers was followed from January 2013 to January 2023. A Cox proportional hazards regression model was designed to evaluate the association of TA-SUA with renal outcomes (defined as serum creatinine doubling, or initiation of dialysis, or kidney transplantation, or progression to end-stage kidney disease). Cox proportional hazards regression with cubic spline functions and smooth curve fitting were used to explore the nonlinear relationship. Detailed evaluations for TA-SUA were also performed using propensity score matching (PSM), subgroup analyses, and sensitivity analyses.</p><p><strong>Results: </strong>A total of 1072 patients were enrolled with a mean follow-up duration of 60.4 ± 5.6 months. The baseline prevalence of hyperuricemia was 46.1% (50.4% in male vs. 37.9% in female). Patients with TA-SUA < 360 μmol/l demonstrated significantly better renal survival compared to those with TA-SUA ≥ 360 μmol/l (adjusted hazard ratio 0.63, 95% confidence interval, 0.41-0.98; P = 0.038). Restriction cubic spline analysis showed a rapid risk increase when TA-SUA exceeded 360 μmol/l, which was confirmed by PSM (P < 0.001). Subgroup analyses and sensitivity analyses showed that patients with eGFR between 30 and 59 ml/min/1.73 m² were the most likely to benefit from maintaining TA-SUA < 360 μmol/l.</p><p><strong>Conclusion: </strong>Long-term maintenance of relatively low TA-SUA levels is independently associated with slowed renal function decline and favorable renal outcomes among patients with type 2 DM with CKD.</p>","PeriodicalId":11192,"journal":{"name":"Diabetes Therapy","volume":" ","pages":"1201-1223"},"PeriodicalIF":4.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13457999/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148410912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}